# WRF Capital

> WRF Capital is a VC fund in Seattle backing Health Care and Biotechnology. See 35 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seattle, United States
- Total investments: 35
- Last investment: Jul 2026
- Lead investor: 9%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/washington-research-foundation/?originalSubdomain=in
- X (Twitter): https://twitter.com/wrfseattle?lang=en
- Website: http://www.wrfseattle.org/wrf-capital.php

WRF Capital is a VC fund in Seattle focused on Health Care and Biotechnology. WRF Capital supports groundbreaking research and early-stage companies that focus on life sciences and enabling technologies. WRF Capital is composed of the Washington Research Foundation and WRF Capital. It is a venture investment arm of the Washington Research Foundation. It works with entrepreneurs, research institutions, other investors, andindustry partners to transform great ideas into successful Washington-based businesses.It was founded in 1981 and is based in Seattle, Washington.

## Contacts

5 contacts available for WRF Capital. Shizune tracks 6 team members at WRF Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/wrf-capital-282a?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 17 | 49% |
| Biotechnology | 14 | 40% |
| Medical | 6 | 17% |
| Therapeutics | 5 | 14% |
| Manufacturing | 5 | 14% |

51 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 29% |
| Seed | 9 | 26% |
| Series B | 5 | 14% |
| Funding Round | 3 | 9% |
| Series C | 2 | 6% |

9 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Loretta Little | Managing Director | 4 | https://shizune.co/investors/profile/loretta-little |
| Sue Coliton | Interim President & Chief Executive Officer | 0 | https://shizune.co/investors/profile/sue-coliton |
| Bill Gates | Co-founder | 0 | https://shizune.co/investors/profile/bill-gates-c230 |
| Hunter Simpson | Founder | 0 | https://shizune.co/investors/profile/hunter-simpson-0bbd |
| Ronald S. Howell | CEO | 0 | https://shizune.co/investors/profile/ronald-s-howell |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Dopl Technologies | Dopl Technologies develops remote robotic ultrasound systems that combine robotics, telepresence, and AI to expand access to diagnostic imaging. Its platform enables healthcare providers to perform ultrasound examinations remotely, helping hospitals and clinics address workforce shortages and improve access to imaging services. The company focuseson diagnostic imaging solutions for rural and underserved healthcare settings. | $6.3M | Seed | Jul 27, 2026 |  |
| Archon Biosciences | Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management. | $20M | Seed | Oct 30, 2024 |  |
| Talus Bio | Talus Bio is a drug discovery biotech startup working on drug development for gene regulators. The company integrates functional proteomics, automated biology, and machine learning to target challenging cancer transcription factors. The MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Factors) platform, developed by thecompany, leverages AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics in a groundbreaking manner. | $11.2M | Seed | Aug 20, 2024 |  |
| Outpace Bio | Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need. | $144M | Series B | Aug 01, 2024 |  |
| Proniras | Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers tocontinue their research work and discover drugs.It was founded in 2016 and is headquartered in Seattle, Washington. | $4.7M | Series B | Feb 01, 2024 |  |
| KayoThera | KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey. | $5.2M | Series A | Jul 19, 2023 |  |
| Wavely Diagnostics | Wavely Diagnostics is pioneering the future of remote digital diagnostics and enabling telehealth growth by leveraging smartphone technology to address pediatric care. | $1.4M | Seed | Jul 12, 2023 |  |
| Somalytics | Somalytics commercializes miniature sensors for eye tracking, human-machine interface, wearables, and industrial safety. It’s the world’s first paper-composite capacitive sensor. It’s paper-thin, consumes little power, and can potentially be disposable. The company was founded in 2021 and is based in Seattle, Washington. | $1.9M | Seed | Aug 30, 2022 |  |
| Wavely Diagnostics | Wavely Diagnostics is pioneering the future of remote digital diagnostics and enabling telehealth growth by leveraging smartphone technology to address pediatric care. | $2.2M | Seed | Feb 08, 2022 |  |
| Wavely Diagnostics | Wavely Diagnostics is pioneering the future of remote digital diagnostics and enabling telehealth growth by leveraging smartphone technology to address pediatric care. | $2.2M | Pre-Seed | Feb 08, 2022 |  |

10 of 35 investments shown.

## Co-investors
- [Washington Research Foundation](https://shizune.co/investors/profile/washington-research-foundation) — VC Fund, 7 deals together
- [Alliance of Angels](https://shizune.co/investors/profile/alliance-of-angels) — VC Fund, 4 deals together
- [W Fund](https://shizune.co/investors/profile/w-fund) — VC Fund, 4 deals together
- [WXR Fund](https://shizune.co/investors/profile/women-in-xr) — VC Fund, 4 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [HealthTech Capital](https://shizune.co/investors/profile/healthtech-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does WRF Capital invest in?

WRF Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact WRF Capital?

Public channels for WRF Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at WRF Capital?

The team at WRF Capital includes Loretta Little (Managing Director), Sue Coliton (Interim President & Chief Executive Officer) and Bill Gates (Co-founder), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co